Islet Sciences Inc. (ISLT) a clinical stage company engaged in the research development and commercialization of therapeutics in the field of diabetes announced today that Cell Transplant Journal released on novel methods of isolating piglet islets a technology owned by Islet Sciences.
“This release is another validator of our approach to tackling this worldwide disease” stated John Steel Islet Sciences Chairman and Chief Executive Officer. “We continue to make solid important strides in executing our business strategy and this paper represents another clear milestone. Importantly with our long term supply agreement with Spring Point Project an FDA approved facility for porcine tissue this novel methodology for potential production of unlimited islet cells provides a crucial foundation for our goal to provide islet cell replacement therapy for persons with insulin dependent diabetes. Islet Sciences initial targeted group are diabetics that have had kidney transplants and may benefit from the opportunity to have islet therapy to augment outcomes."
“This work is exciting in that we have developed a novel method of producing viable piglet islets that is reproducible and scalable in doses of islets that will be required to transplant into patients with insulin dependent diabetes” stated Dr. Jonathan Lakey Chief Scientific Officer and Chairman of the Scientific Advisory Board of Islet Sciences.
Below is a link and copy of the Abstract:
In vitro maturation of viable islets from partially digested young pig pancreas
Isolation of islets from market size pig is costly with considerable islet losses from fragmentation occurring during isolation and tissue culture. Fetal and neonatal pigs yield insulin unresponsive islet-like cell clusters that become glucose responsive after extended periods of time. Both issues impact clinical applicability and commercial scale-up. We have focused our efforts on a cost-effective scalable method of isolating viable insulin responsive islets. Young Yorkshire pigs (mean age 20 days range 4-30 days) underwent rapid pancreatectomy (<5 min) and partial digestion using low dose collagenase followed by in vitro culture at 37°C and 5% CO2 for up to 14 days. Islet viability was assessed using FDA/PI or Newport Green and function assessed using glucose stimulated insulin release (GSIR) assay. Islet yield was performed using enumeration of dithizone stained aliquots. Young porcine (YP) islet yield at dissociation was 12.6+2.1 x10³ IE (mean+SEM) per organ and increased to 33.3+6.4x10³ IE after 7 days of in vitro culture. Viability was 97.3+7% at dissociation and remained over 90% viable after 11 days in tissue culture (n=ns). Glucose responsiveness increased throughout maturation in culture. The stimulation index (SI) of the islets increased from 1.7±2 on culture day 3 to 2.58±0.5 on culture day 7. These results suggested that this method is both efficient and scalable for isolating and maturing insulin responsive porcine islets in culture.
About Islet Sciences Inc.
Islet Sciences is a development-stage biotechnology company with patented technologies focused on infusion therapy for people with insulin-dependent diabetes. The Company's infusion technology includes methods for the culturing isolation maturation and immunoprotection (microencapsulation) of islet cells. The Company's mission includes the introduction of commercial products relevant to the insulin dependent diabetes marketplace including diagnostics and anti inflammatory compounds. For more information: www.isletsciences.com
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements for Islet Sciences reflect current expectations as of the date of this press release and involve certain risks and uncertainties. Actual results could differ materially from those anticipated in these forward- looking statements as a result of various factors. Factors that could cause future results to materially differ from the recent results or those projected in forward-looking statements include the risks described in the Islet Science's reports filed with the Securities and Exchange Commission. The companies' further development is highly dependent on future medical and research developments and market acceptance which is outside their control.Business Wire
Last updated on: 12/04/2013